Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Pharmacokinetics of CX2101A in Healthy Adults
NCT06864182Phase 1Completed
- Sponsor
- HeraNova Lifesciences
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cx2101a in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by HeraNova Lifesciences. Primary endpoints: Pharmacokinetic profile of CX2101A, Pharmacokinetic profile of metabolite CX210101 and 1 more. Started Mar 2024; status: completed.
02
Drugs
cx2101a
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06864182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864182.